T-cell exhaustion may limit long-term immunity in COVID-19 patients
Researchers suggest patients who develop mild COVID-19 may not be able to fight reinfection very effectively because their CD8+ T cells show signs of exhaustion.
List view / Grid view
Researchers suggest patients who develop mild COVID-19 may not be able to fight reinfection very effectively because their CD8+ T cells show signs of exhaustion.
21 January 2021 | By Yokogawa Life Innovations
Watch our on-demand webinar and learn how image-based phenotypic screening relies on extraction of multivariate information from cells cultured in a large number of screened conditions. In this webinar, we explore the application of complex and biologically relevant model systems for drug screening, such as small intestinal organoids.
This tissue-specific handbook brings you key publications, in-house protocols and troubleshooting recommendations for your organoid cell culture.
According to a Public Health England study, prior SARS-CoV-2 infection provides 83 percent protection against reinfection but may not stop individuals spreading COVID-19.
By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
Remdesivir is being prescribed under FDA emergency use authorisation as a treatment for patients with COVID-19.
This webinar from Bio-Techne demonstrates how to use a novel in vitro flow cytometry-based assay to monitor SARS-CoV-2 binding to ACE-2.
LifeArc and the Medical Research Council have funded a new drug screening facility that will be established to accelerate COVID-19 drug discovery.
Researchers suggest that identifying new treatments for autoimmune diseases requires studying the immune system AND target tissues together.
A new analysis suggests SARS-CoV-2-specific antibodies remain relatively stable for eight months and Spike protein-specific memory B cells increase in number over time.
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
In this article, Ramya Sriram describes how data science is driving innovations in medical biotechnology and genomics.
Study identifies a promising new compound that can open constricted airways and could be a promising treatment for obstructive lung diseases.
Computational drug screening has shown that chemotherapy drug pralatrexate could potentially be repurposed to treat COVID-19.
Dr Isaac Karimi and his team explain how compounds to treat COVID-19 could be found in Kurdish ethnomedicine, selecting some plants for computational drug discovery.